Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus

Ruining Zhang,Qingxing Xie,Xi Lu,Rongping Fan,Nanwei Tong

DOI: https://doi.org/10.1186/s13098-024-01325-9

2024-05-14

Diabetology & Metabolic Syndrome

Abstract:Diabetes mellitus is one of the most significant global burden diseases. It is well established that a chronic, systemic, low-grade inflammatory condition is strongly correlated with type 2 diabetes mellitus (T2D) and the development of target-organ damage (TOD). Sodium-glucose cotransporter inhibitors (SGLTis), novel oral drugs for the treatment of diabetes, act mainly by reducing glucose reabsorption in proximal renal tubules and/or the intestine. Several high-quality clinical trials and large observational studies have revealed that SGLTis significantly improve cardiovascular and renal outcomes in T2D patients. Increasing evidence suggests that this is closely related to their anti-inflammatory properties, which are mainly manifested by a reduction in plasma concentrations of inflammatory biomarkers. This review analyses the potential mechanisms behind the anti-inflammatory effects of SGLTis in diabetes and presents recent evidence of their therapeutic efficacy in treating diabetes and related TOD.

endocrinology & metabolism

What problem does this paper attempt to address?

The paper primarily explores the anti-inflammatory effects and mechanisms of sodium-glucose co-transporter inhibitors (SGLTis) in type 2 diabetes (T2D). Specifically, the paper attempts to address the following issues:

1. **The relationship between inflammation and type 2 diabetes**: The paper points out that chronic, systemic low-grade inflammation is closely related to the development of type 2 diabetes. Inflammatory markers such as tumor necrosis factor (TNF-α), interleukin (IL-6), and C-reactive protein (CRP) are significantly elevated in the plasma of patients with type 2 diabetes.

2. **Anti-inflammatory effects of SGLTis**: Studies have found that SGLTis can significantly reduce the levels of inflammatory markers, including TNF-α, IL-1β, IL-6, etc. These anti-inflammatory effects may be achieved through various mechanisms, such as weight reduction, lowering uric acid levels, and reducing oxidative stress.

3. **Cardiorenal protective effects of SGLTis**: Multiple clinical trials and observational studies have shown that SGLTis can not only significantly improve cardiovascular and renal outcomes but also significantly reduce cardiovascular events, hospitalization rates for heart failure, and all-cause mortality.

4. **Specific anti-inflammatory mechanisms of SGLTis**: The paper provides a detailed analysis of the anti-inflammatory mechanisms of SGLTis, including reducing the expression of inflammatory markers, affecting inflammatory signaling pathways, promoting M2 macrophage polarization, and inhibiting the activation of the NLRP3 inflammasome.

In summary, this paper aims to systematically collect and analyze the anti-inflammatory effects of SGLTis in type 2 diabetes and its related inflammation, and to explore their potential mechanisms.